

(I)

a compound of formula I wherein: X^1 is N or CH; X^2 is NR^a, O or S; X^3 is $C(=O)CH_2$, $(CR^4{}_2)_{1-3}$, CH_2NR^b, C(=O), $C(=O)NR^b$ or C(=O)O with the proviso that: when X^3 is CH_2NR^b, the tricyclic moiety of (I) is a 6,7,8,9-tetrahydro-1,2,2a^1,6,8-pentaazabenzo[cd]azulene, when X^3 is $C(=O)NR^b$, the tricyclic moiety of (I) is a 8,9-dihydro-1,2,2a^1,6,8-pentaazabenzo[cd]azulen-7(6H)-one, when X^3 is $C(=O)CH_2$, the tricyclic moiety of (I) is a 8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one, and when X^3 is C(=O)O, the tricyclic moiety of (I) is a 6H-8-oxa-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(9H)-one; X^4 is CR^2R^3 or NR^3 with the proviso that when X^4 is NR^3, X^2 is NR^a and X^3 is C(=O); R^1 is (i) a 4 to 7 membered saturated or partially unsaturated heterocyclyl or, (ii) a optionally substituted 5 to 6 membered heteroaryl; R^2 is selected from the group consisting of: (a) C_{1-10} alkyl, (b) C_{2-10} alkenyl, (c) C_{1-10} haloalkyl, (d) C_{3-7} cycloalkyl or C_{3-7} cycloalkyl-C_{1-6} alkyl, (e) C_{3-7} halocycloalkyl or C_{3-7} halocycloalkyl-C_{1-6} alkyl, (f) C_{1-10} hydroxyalkyl or C_{1-10} dihydroxyalkyl, (g) C_{1-3} alkoxy-C_{1-6} alkyl, (h) C_{1-3} alkylthio-C_{1-6} alkyl, (i) C_{1-10} cyanoalkyl, (j) phenyl, phenyl-C_{1-3} alkyl, phenoxy or benzyloxy-C_{1-3} alkyl, (k) heteroaryl, heteroaryl-C_{1-3} alkyl or heteroaryloxy wherein said heteroaryl moiety is selected from the group consisting of pyrazolyl, imidiazolyl, oxazolyl, isoazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrid-2(1H)-one and 1-alkylpyrid-2(1H)-one and each said heteroaryl is independently optionally substituted with one or more groups selected from the group consisting of halogen, hydroxyl, oxide, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cyano, C_{3-6} cycloalkyl and C_{1-6} alkyl wherein said C_{1-6} alkyl is optionally independently substituted with one or more groups independently selected from halogen, oxo, hydroxyl or C_{1-6} alkoxy; and, (l) phenylthio or phenylthio-C_{1-6} alkyl; $R^3$and R^4 is independently in each occurrence hydrogen or C_{1-3} alkyl; R^a and R^b are independently hydrogen or C_{1-3} alkyl; or, a pharmaceutically salt thereof; wherein any phenyl moiety is optionally substituted one or more halogen, cyano, hydroxyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy or C_{1-6} alkyl wherein said C_{1-6} alkyl is optionally independently substituted with one or more groups independently selected from halogen, oxo, hydroxyl or C_{1-6} alkoxy; and, wherein each cycloalkyl is independently optionally substituted with one to three groups halogen, C_{1-6} haloalkyl,C_{1-6} alkoxy or C_{1-6} haloalkoxy. In one example, there is disclosed a compound of formula I wherein:



(I)

X^1 is N or CH; X^2 is NR^a, O or S; X^3 is $(CR^4_2)_{1-3}$, CH_2NR^b, C(=O), $C(=O)NR^b$ or C(=O)O with the proviso that: when X^3 is CH_2NR^b, the tricyclic moiety of (I) is a 6,7,8,9-tetrahydro-1,2,2a^1,6,8-pentaazabenzo[cd]azulene, when X^3 is $C(=O)NR^b$, the tricyclic moiety of (I) is a 8,9-dihydro-1,2,2a^1,6,8-pentaazabenzo[cd]azulen-7(6H)-one, and when X^3 is C(=O)O, the tricyclic moiety of (I) is a 6H-8-oxa-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(9H)-one; X^4 is CR^2R^3 or NR^3 with the proviso that when X^4 is NR3, X^2 is NR^a and X^3 is C(=O); R^1 is (i) a 4 to 7 membered saturated or partially unsaturated heterocyclyl or, (ii) a optionally substituted 5 to 6 membered heteroaryl; R^2 is selected from the group consisting of: (a) C_{1-10} alkyl, (b) C_{2-10} alkenyl, (c) C_{1-10} haloalkyl, (d) C_{3-7} cycloalkyl or C_{3-7} cycloalkyl-C_{1-6} alkyl, (e) C_{3-7} halocycloalkyl or C_{3-7} halocycloalkyl-C_{1-6} alkyl, (f) C_{1-10} hydroxyalkyl or C_{1-10} dihydroxyalkyl, (g) C_{1-3} alkoxy-C_{1-6} alkyl, (h) C_{1-3} alkylthio-C_{1-6} alkyl, (i) C_{1-10} cyanoalkyl, (j) phenyl, phenyl-C_{1-3} alkyl, phenoxy or benzyloxy-C_{1-3} alkyl, (k) heteroaryl, heteroaryl-C_{1-3} alkyl or heteroaryloxy wherein said heteroaryl moiety is selected from the group consisting of pyrazolyl, imidiazolyl, oxazolyl, isoazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrid-2(1H)-one and 1-alkylpyrid-2(1H)-one and each said heteroaryl is independently optionally substituted with one or more groups selected from the group consisting of halogen, hydroxyl, oxide, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cyano, C_{3-6} cycloalkyl and C_{1-6} alkyl wherein said C_{1-6} alkyl is optionally independently substituted with one or more groups independently selected from halogen, oxo, hydroxyl or C_{1-6} alkoxy; and, (l) phenylthio or phenylthio-C_{1-6} alkyl; $R^3$and R^4 is independently in each occurrence hydrogen or C_{1-3} alkyl; R^a and R^b are independently hydrogen or C_{1-3} alkyl; or, a pharmaceutically salt thereof; wherein any phenyl moiety is optionally substituted one or more halogen, cyano, hydroxyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy or C_{1-6} alkyl wherein said C_{1-6} alkyl is optionally independently substituted with one or more groups independently selected from halogen, oxo, hydroxyl or C_{1-6} alkoxy; and, wherein each cycloalkyl is independently optionally substituted with one to three groups halogen, C_{1-6} haloalkyl,C_{1-6} alkoxy or C_{1-6} haloalkoxy. In another aspect, the present invention refers to a pharmaceutical composition comprising a compound as disclosed herein and

at least one pharmaceutically acceptable carrier, excipient or diluent. In yet another aspect, the present invention refers to use of a compound as disclosed herein in the manufacture of a medicament for treating or ameliorating the severity of cancer in a patient in need thereof. In a further aspect, the present invention refers to use of a compound as disclosed herein in the manufacture of a medicament for the treatment of cancer. In yet another aspect, the present invention refers to a pharmaceutical composition comprising a compound as disclosed herein for us in the treatment of a hyperproliferative disease. In one aspect, the present invention refers to a compound as disclosed herein, wherein the compound is selected from 4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; (R)-4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; (S)-4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; 3-benzyl-5-methyl-7-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-3H-1,1,2a^1,3,5-pentaazaacenaphthylen-4(5H)-one;9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one; (S)-9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one; (R)-9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one; 4-(9-((4-chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; (R)-4-(9-((4-chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; or (S)-4-(9-((4-Chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; or a pharmaceutically acceptable salt thereof. In another aspect, the present invention refers toA pharmaceutical composition comprising a compound as disclosed herein, wherein the compound is selected from 4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; (R)-4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; (S)-4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-

amine; 3-benzyl-5-methyl-7-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-3H-1,1,2a^1,3,5-pentaazaacenaphthylen-4(5H)-one; 9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one; (S)-9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one; (R)-9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one; 4-(9-((4-chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; (R)-4-(9-((4-chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; or (S)-4-(9-((4-Chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier, excipient or diluent.

We claim:

1. A compound of formula I wherein:



(I)

X^1 is N or CH;

X^2 is NR^a, O or S;

X^3 is $C(=O)CH_2$, $(CR^4_2)_{1-3}$, CH_2NR^b, C(=O), $C(=O)NR^b$ or C(=O)O with the proviso that:

when X^3 is CH_2NR^b, the tricyclic moiety of (I) is a 6,7,8,9-tetrahydro-1,2,2a^1,6,8-pentaazabenzo[cd]azulene,

when X^3 is $C(=O)NR^b$, the tricyclic moiety of (I) is a 8,9-dihydro-1,2,2a^1,6,8-pentaazabenzo[cd]azulen-7(6H)-one,

when X^3 is $C(=O)CH_2$, the tricyclic moiety of (I) is a 8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one, and

when X^3 is C(=O)O, the tricyclic moiety of (I) is a 6H-8-oxa-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(9H)-one;

X^4 is CR^2R^3 or NR^3 with the proviso that when X^4 is NR^3, X^2 is NR^a and X^3 is C(=O);

R^1 is (*i*) a 4 to 7 membered saturated or partially unsaturated heterocyclyl or, (*ii*) a optionally substituted 5 to 6 membered heteroaryl;

R^2 is selected from the group consisting of:

(a) C_{1-10} alkyl,

(b) C_{2-10} alkenyl,

(c) C_{1-10} haloalkyl,

(d) C_{3-7} cycloalkyl or C_{3-7} cycloalkyl-C_{1-6} alkyl,

(e) C_{3-7} halocycloalkyl or C_{3-7} halocycloalkyl-C_{1-6} alkyl,

(f) C_{1-10} hydroxyalkyl or C_{1-10} dihydroxyalkyl,

(g) C_{1-3} alkoxy-C_{1-6} alkyl,

(h) C_{1-3} alkylthio-C_{1-6} alkyl,

(i) C_{1-10} cyanoalkyl,

(j) phenyl, phenyl-C_{1-3} alkyl, phenoxy or benzyloxy-C_{1-3} alkyl,

(k) heteroaryl, heteroaryl-C_{1-3} alkyl or heteroaryloxy wherein said heteroaryl moiety is selected from the group consisting of pyrazolyl, imidiazolyl, oxazolyl, isoazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrid-2(1H)-one and 1-alkylpyrid-2(1H)-one and each said heteroaryl is independently optionally substituted with one or more groups selected from the group consisting of halogen, hydroxyl, oxide, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cyano, C_{3-6} cycloalkyl and C_{1-6} alkyl wherein said C_{1-6} alkyl is optionally independently substituted with one or more groups independently selected from halogen, oxo, hydroxyl or C_{1-6} alkoxy; and,

(l) phenylthio or phenylthio-C_{1-6} alkyl;

$\mathbf{R^3}$and $\mathbf{R^4}$ is independently in each occurrence hydrogen or C_{1-3} alkyl;

$\mathbf{R^a}$ and $\mathbf{R^b}$ are independently hydrogen or C_{1-3} alkyl; or,

a pharmaceutically salt thereof;

wherein any phenyl moiety is optionally substituted one or more halogen, cyano, hydroxyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy or C_{1-6} alkyl wherein said C_{1-6} alkyl is optionally independently substituted with one or more groups independently selected from halogen, oxo, hydroxyl or C_{1-6} alkoxy; and,

wherein each cycloalkyl is independently optionally substituted with one to three groups halogen, C_{1-6} haloalkyl,C_{1-6} alkoxy or C_{1-6} haloalkoxy.

2. A compound according to claim 1 wherein $\mathbf{X^2}$ is $\mathbf{NR^a}$, $\mathbf{X^3}$ is CH_2 and $\mathbf{X^4}$ is $\mathbf{CR^2R^3}$.

3. A compound according to claim 1 wherein $\mathbf{X^2}$ is $\mathbf{NR^a}$, $\mathbf{X^3}$ is C(=O) and $\mathbf{X^4}$ is $\mathbf{CR^2R^3}$.

4. A compound according to claim 1 wherein $\mathbf{X^2}$ is $\mathbf{NR^a}$, $\mathbf{X^3}$ is $(CH_2)_2$ and $\mathbf{X^4}$ is $\mathbf{CR^2R^3}$.

5. A compound according to claim 1 wherein $\mathbf{X^2}$ is $\mathbf{NR^a}$, $\mathbf{X^3}$ is $CH_2\mathbf{NR^b}$ and $\mathbf{X^4}$ is $\mathbf{CR^2R^3}$.

6. A compound according to claim 1 wherein $\mathbf{X^2}$ is $\mathbf{NR^a}$, $\mathbf{X^3}$ is $C(=O)CH_2$ and $\mathbf{X^4}$ is $\mathbf{CR^2R^3}$.

7. A compound according to claim 1 wherein $\mathbf{X^2}$ is $\mathbf{NR^a}$, $\mathbf{X^3}$ is $C(=O)\mathbf{NR^b}$ and $\mathbf{X^4}$ is $\mathbf{CR^2R^3}$.

8. A compound according to claim 1 wherein $\mathbf{X^2}$ is O, $\mathbf{X^3}$ is CH_2 and $\mathbf{X^4}$ is $\mathbf{CR^2R^3}$.

9. A compound according to claim 1 wherein $\mathbf{X^2}$ is O, $\mathbf{X^3}$ is $(CH_2)_2$ and $\mathbf{X^4}$ is $\mathbf{CR^2R^3}$.

10. A compound according to claim 1 wherein wherein $\mathbf{X^2}$ is $\mathbf{NR^a}$, $\mathbf{X^3}$ is C(=O) and $\mathbf{X^4}$ is $\mathbf{NR^3}$.

11. A compound according to any of claims 2 to 8 wherein $\mathbf{R^2}$ is optionally substituted phenyl-C_{1-3} alkyl and $\mathbf{R^3}$ is hydrogen.

12. A compound according to any of claims 2 to8 wherein $\mathbf{R^2}$ is optionally substituted heteroaryl-C_{1-3} alkyl and $\mathbf{R^3}$ is hydrogen.

13. A compound according to any of claims 2 to 8 wherein $\mathbf{R^2}$ is optionally substituted phenoxy or heteroaryloxy and $\mathbf{R^3}$ is hydrogen.

14. A compound according to any of claims 10 to 12 wherein $\mathbf{CR^2R^3}$ is in the (S) configuration.

15. A compound according to any of claims 10 to 12 wherein $\mathbf{CR^2R^3}$ is in the (R) configuration.

16. The compound according to any of claims 10 to 14 wherein:
$\mathbf{X^2}$ is O,
$\mathbf{X^3}$ is CH_2 or $(CH_2)_2$, and,
$\mathbf{R^1}$ is tetrahydropyranyl, tetrahydrofuranyl, oxetanyl or optionally substituted pyrazolyl.

17. The compound according to claim 15 wherein $\mathbf{X^3}$ is $(CH_2)_2$ and $\mathbf{R^1}$ is optionally substituted pyrazolyl.

18. The compound according to claim 16 wherein $\mathbf{R^2}$ is optionally substituted benzyl.

19. The compound according to claim 16 wherein $\mathbf{R^2}$ is optionally substituted heteroaryl-methyl.

20. The compound according to claim 16 wherein $\mathbf{R^2}$ is optionally substituted phenoxy or heteraryloxy.

21. The compound according to any of claims 17 to 19 wherein $\mathbf{R^1}$ is 1-methyl-1H-pyrazol-5-yl).

22. The compound according to claim 20 wherein $\mathbf{R^2}$ is optionally substituted benzyl.

23. The compound according to claim 20 wherein $\mathbf{R^2}$ is benzyl.

24. The compound according to claim 20 wherein $\mathbf{R^2}$ is optionally substituted (1H-pyrazol-1-yl)methyl.

25. The compound according to claim 23 wherein $\mathbf{R^2}$ is (4-chloro-1H-pyrazol-1-yl)methyl.

26. The compound according to claim 23 wherein $\mathbf{R^2}$ is (4-trifluoromethyl-1H-pyrazol-1-yl)methyl.

27. The compound according to claim 23 wherein $\mathbf{R^2}$ is (4-cyclopropyl-1H-pyrazol-1-yl)methyl.

28. The compound according to claim 20 wherein R^2 is optionally substituted phenoxy.

29. The compound according to any of claims 1 to 27 selected from the list consisting of compounds I-1 to I-109 in TABLE 1.

30. A compound according to any one of claims 1 to 28 for use in the treatment of cancer.

31. A compound of any one of claims 1 to 28 for use as a medicament.

32. A compound of any one of claims 1 to 28 for use in therapy.

33. A pharmaceutical composition comprising a compound according to any one of claims 1 to 28 and at least one pharmaceutically acceptable carrier, excipient or diluent.

34. Use of a compound according to any one of claims 1 to 28 in the manufacture of a medicament for treating or ameliorating the severity of cancer in a patient in need thereof.

35. The use according to claim 33 wherein said cancer is selected from the group consisting of adenoma, bladder cancer, brain cancer, breast cancer, colon cancer, epidermal carcinoma, follicular carcinoma, cancer of the genitourinary tract, glioblastoma, Hodgkin's disease, head and neck cancers, hepatoma, keratoacanthoma, kidney cancer, large cell carcinoma, leukemias, lung adenocarcinoma, lung cancer, lymphoid disorders, melanoma and non-melanoma skin cancer, myelodysplastic syndrome, neuroblastoma, non-Hodgkins lymphoma, ovarian cancer, papillary carcinoma, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, small cell carcinoma, testicular cancer, tetracarcinomas, thyroid cancer, and undifferentiated carcinoma.

36. The use according to claim 33 wherein said cancer is selected from the group consisting of melanoma, pancreatic cancer, thyroid cancer, colorectal cancer, lung cancer, breast cancer and ovarian cancer.

37. The use according to claim 33 wherein said cancer is selected from the group consisting of acute myelogenous leukemia, chronic myelomonocytic leukemia, chronic myelogenous leukemia, multiple myeloma and myeloid leukemia.

38. The use according to claim 33 wherein a compound of any of claims 1 to 28 is to be co-administered with at least one other chemotherapeutic agent used to treat or ameliorate cancer.

39. Use of a compound of any one of claims 1 to 28 in the manufacture of a medicament for the treatment of cancer.

40. A pharmaceutical composition comprising a compound of any one of claims 1 to 28 for use in the treatment of cancer.

41. A compound according to claim 1 wherein the compound is selected from:
4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine;
(R)-4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine;

(S)-4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine;
3-benzyl-5-methyl-7-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-3H-1,1,2a^1,3,5-pentaazaacenaphthylen-4(5H)-one;
9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one;
(*S*)-9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one;
(*R*)-9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one;
4-(9-((4-chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine;
(*R*)-4-(9-((4-chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; or
(*S*)-4-(9-((4-Chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine;
or a pharmaceutically acceptable salt thereof.

42. A pharmaceutical composition comprising a compound according to claim 1 wherein the compound is selected from:
4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine;
(R)-4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine;
(S)-4-(9-(4-chlorobenzyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine;
3-benzyl-5-methyl-7-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-3H-1,1,2a^1,3,5-pentaazaacenaphthylen-4(5H)-one;
9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one;
(*S*)-9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one;
(*R*)-9-(4-chlorobenzyl)-6-methyl-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-8,9-dihydro-1,2,2a^1,6-tetraazabenzo[cd]azulen-7(6H)-one;

4-(9-((4-chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; (*R*)-4-(9-((4-chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; or (*S*)-4-(9-((4-Chloro-1H-pyrazol-1-yl)methyl)-8,9-dihydro-7H-6-oxa-1,2,2a^1-triazabenzo[cd]azulen-4-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine; or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier, excipient or diluent.